518 related articles for article (PubMed ID: 26819453)
1. The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.
Ruella M; Kenderian SS; Shestova O; Fraietta JA; Qayyum S; Zhang Q; Maus MV; Liu X; Nunez-Cruz S; Klichinsky M; Kawalekar OU; Milone M; Lacey SF; Mato A; Schuster SJ; Kalos M; June CH; Gill S; Wasik MA
Clin Cancer Res; 2016 Jun; 22(11):2684-96. PubMed ID: 26819453
[TBL] [Abstract][Full Text] [Related]
2. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
Sun B; Shah B; Fiskus W; Qi J; Rajapakshe K; Coarfa C; Li L; Devaraj SG; Sharma S; Zhang L; Wang ML; Saenz DT; Krieger S; Bradner JE; Bhalla KN
Blood; 2015 Sep; 126(13):1565-74. PubMed ID: 26254443
[TBL] [Abstract][Full Text] [Related]
3. HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma.
Jacobson C; Kopp N; Layer JV; Redd RA; Tschuri S; Haebe S; van Bodegom D; Bird L; Christie AL; Christodoulou A; Saur A; Tivey T; Zapf S; Bararia D; Zimber-Strobl U; Rodig SJ; Weigert O; Weinstock DM
Blood; 2016 Nov; 128(21):2517-2526. PubMed ID: 27742706
[TBL] [Abstract][Full Text] [Related]
4. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
Chiron D; Di Liberto M; Martin P; Huang X; Sharman J; Blecua P; Mathew S; Vijay P; Eng K; Ali S; Johnson A; Chang B; Ely S; Elemento O; Mason CE; Leonard JP; Chen-Kiang S
Cancer Discov; 2014 Sep; 4(9):1022-35. PubMed ID: 25082755
[TBL] [Abstract][Full Text] [Related]
5. Promising efficacy of novel BTK inhibitor AC0010 in mantle cell lymphoma.
Yan X; Zhou Y; Huang S; Li X; Yu M; Huang J; Wang J; Ma Z; Jin J; Pan J; Li C; Li F; Jin J
J Cancer Res Clin Oncol; 2018 Apr; 144(4):697-706. PubMed ID: 29392403
[TBL] [Abstract][Full Text] [Related]
6. p110α Inhibition Overcomes Stromal Cell-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma.
Guan J; Huang D; Yakimchuk K; Okret S
Mol Cancer Ther; 2018 May; 17(5):1090-1100. PubMed ID: 29483220
[TBL] [Abstract][Full Text] [Related]
7. Targeting protein kinase C in mantle cell lymphoma.
Rauert-Wunderlich H; Rudelius M; Ott G; Rosenwald A
Br J Haematol; 2016 May; 173(3):394-403. PubMed ID: 26914495
[TBL] [Abstract][Full Text] [Related]
8. Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells.
Ma J; Lu P; Guo A; Cheng S; Zong H; Martin P; Coleman M; Wang YL
Br J Haematol; 2014 Sep; 166(6):849-61. PubMed ID: 24957109
[TBL] [Abstract][Full Text] [Related]
9. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis.
Cinar M; Hamedani F; Mo Z; Cinar B; Amin HM; Alkan S
Leuk Res; 2013 Oct; 37(10):1271-7. PubMed ID: 23962569
[TBL] [Abstract][Full Text] [Related]
10. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.
Cheah CY; Chihara D; Romaguera JE; Fowler NH; Seymour JF; Hagemeister FB; Champlin RE; Wang ML
Ann Oncol; 2015 Jun; 26(6):1175-1179. PubMed ID: 25712454
[TBL] [Abstract][Full Text] [Related]
11. Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.
Liu M; Deng H; Mu J; Li Q; Pu Y; Jiang Y; Deng Q; Qian Z
Cancer Sci; 2021 Jul; 112(7):2642-2651. PubMed ID: 33932067
[TBL] [Abstract][Full Text] [Related]
12. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
Chiron D; Dousset C; Brosseau C; Touzeau C; Maïga S; Moreau P; Pellat-Deceunynck C; Le Gouill S; Amiot M
Oncotarget; 2015 Apr; 6(11):8750-9. PubMed ID: 25797245
[TBL] [Abstract][Full Text] [Related]
13. CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study.
Minson A; Hamad N; Cheah CY; Tam C; Blombery P; Westerman D; Ritchie D; Morgan H; Holzwart N; Lade S; Anderson MA; Khot A; Seymour JF; Robertson M; Caldwell I; Ryland G; Saghebi J; Sabahi Z; Xie J; Koldej R; Dickinson M
Blood; 2024 Feb; 143(8):673-684. PubMed ID: 37883795
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effect of ibrutinib and CD19 CAR-T cells on Raji cells in vivo and in vitro.
Liu M; Wang X; Li Z; Zhang R; Mu J; Jiang Y; Deng Q; Sun L
Cancer Sci; 2020 Nov; 111(11):4051-4060. PubMed ID: 32876369
[TBL] [Abstract][Full Text] [Related]
15. Ibrutinib for mantle cell lymphoma.
Tucker DL; Rule SA
Future Oncol; 2016 Feb; 12(4):477-91. PubMed ID: 26759179
[TBL] [Abstract][Full Text] [Related]
16. CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.
Kagiyama Y; Fujita S; Shima Y; Yamagata K; Katsumoto T; Nakagawa M; Honma D; Adachi N; Araki K; Kato A; Inaki K; Ono Y; Fukuhara S; Kobayashi Y; Tobinai K; Kitabayashi I
Cancer Sci; 2021 Jun; 112(6):2314-2324. PubMed ID: 33792119
[TBL] [Abstract][Full Text] [Related]
17. Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor-BTK Signaling Pathway.
Zhang Q; Wang HY; Liu X; Nunez-Cruz S; Jillab M; Melnikov O; Nath K; Glickson J; Wasik MA
J Immunol; 2019 Oct; 203(8):2043-2048. PubMed ID: 31534006
[TBL] [Abstract][Full Text] [Related]
18. MCIR1: A patient-derived mantle cell lymphoma line for discovering new treatments for ibrutinib resistance.
Wu X; Nowakowski KE; Abeykoon JP; Manske M; Stenson MJ; Timm MM; Hanson CA; Van Dyke DL; Dasari S; Witzig TE
Eur J Haematol; 2021 Oct; 107(4):458-465. PubMed ID: 34214199
[TBL] [Abstract][Full Text] [Related]
19. Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib.
Qin JS; Johnstone TG; Baturevych A; Hause RJ; Ragan SP; Clouser CR; Jones JC; Ponce R; Krejsa CM; Salmon RA; Ports MO
J Immunother; 2020 May; 43(4):107-120. PubMed ID: 31899702
[TBL] [Abstract][Full Text] [Related]
20. Bruton tyrosine kinase degradation as a therapeutic strategy for cancer.
Dobrovolsky D; Wang ES; Morrow S; Leahy C; Faust T; Nowak RP; Donovan KA; Yang G; Li Z; Fischer ES; Treon SP; Weinstock DM; Gray NS
Blood; 2019 Feb; 133(9):952-961. PubMed ID: 30545835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
